Wegovy, a popular weight-loss drug, is now covered by Medicare and Medicaid for patients with heart disease. A recent trial showed that it reduced the risk of heart attack, stroke, and cardiovascular disease by 20%. The drug, containing the active ingredient semaglutide, mimics a naturally occurring hormone and helps reduce cravings and blood sugar levels. This coverage trend could spur other drug manufacturers to seek approval for similar medications. Although expensive, the demand for Wegovy is high, and analysts predict significant healthcare spending. As the drug becomes more prescribed, there is concern about potential side effects and the unintended consequence of patients seeking diagnoses of heart disease for Medicare coverage. Despite these challenges, the expanded access to Wegovy could have significant positive impacts on cardiovascular disease and the obesity epidemic in America.